A O
novel O
homeodomain O
- O
encoding O
gene O
is O
associated O
with O
a O
large O
CpG O
island O
interrupted O
by O
the O
myotonic B
dystrophy I
unstable O
( O
CTG O
) O
n O
repeat O
. O

Other O
tumor O
types O
found O
in O
BRCA1 O
mutation O
/ O
haplotype O
carriers O
included O
prostatic O
, O
pancreas O
, O
skin O
, O
and O
lung O
cancer O
, O
a O
malignant O
melanoma O
, O
an O
oligodendroglioma B
, O
and O
a O
carcinosarcoma B
. O

The O
family O
does O
not O
appear O
to O
be O
remarkable O
in O
the O
spectrum O
of O
tumours O
, O
and O
there O
is O
loss O
of O
the O
wild O
- O
type O
allele O
in O
a O
leiomyosarcoma B
from O
the O
proband O
. O

However O
, O
both O
models O
lack O
other O
frequent O
DM O
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy O
, O
myotonia O
, O
cataract O
and O
male B
- I
infertility I
. O

To O
elucidate O
the O
role O
of O
DMPK O
in O
DM O
pathogenesis O
we O
have O
developed O
Dmpk B
deficient I
( O
Dmpk O
- O
/ O
- O
) O
mice O
. O

Muscles O
from O
mature O
mice O
show O
variation O
in O
fibre O
size O
, O
increased O
fibre B
degeneration I
and O
fibrosis B
. O

In O
addition O
, O
15 O
papillary O
renal O
cell O
tumours O
and O
ten O
renal B
oncocytomas I
, O
which O
are O
characterized O
by O
genetic O
changes O
other O
than O
loss O
of O
chromosome O
3p O
sequences O
, O
were O
analysed O
for O
mutation O
of O
the O
VHL O
gene O
. O

Although O
this O
microsatellite B
instability I
has O
been O
attributed O
to O
mutations O
in O
four O
DNA O
mismatch O
repair O
genes O
in O
hereditary O
nonpolyposis O
colorectal O
cancer O
( O
HNPCC O
) O
kindreds O
, O
many O
sporadic O
tumours O
exhibit O
instability O
but O
no O
detectable O
mutations O
in O
these O
genes O
. O

The O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
gene O
( O
CHRNA4 O
) O
is O
located O
in O
the O
candidate O
region O
for O
three O
different O
phenotypes O
benign O
familial O
neonatal O
convulsions O
, O
autosomal B
dominant I
nocturnal I
frontal I
lobe I
epilepsy I
, O
and O
low O
- O
voltage O
EEG O
. O

Recently O
, O
a O
missense O
mutation O
in O
transmembrane O
domain O
2 O
of O
CHRNA4 O
was O
found O
to O
be O
associated O
with O
autosomal B
dominant I
nocturnal I
frontal I
lobe I
epilepsy I
in O
one O
extended O
pedigree O
. O

Targeted O
disruption O
of O
ATM O
leads O
to O
growth O
retardation O
, O
chromosomal B
fragmentation I
during I
meiosis I
, O
immune O
defects O
, O
and O
thymic O
lymphoma O
. O

HPRT B
- I
APRT I
- I
deficient I
mice O
are O
not O
a O
model O
for O
lesch O
- O
nyhan O
syndrome O
. O

Administration O
of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
APRT O
) O
in O
HPRT O
- O
deficient O
mice O
has O
produced O
the O
suggestion O
that O
deficiency B
of I
APRT I
in O
combination O
with O
HPRT O
- O
deficiency O
in O
mice O
may O
lead O
to O
self O
- O
mutilation O
behavior O
[ O
C O
. O
L O
. O
Wu O
and O
D O
. O
W O
. O
Melton O
( O
1993 O
) O
Nature O
Genet O
. O
3 O
, O
235 O
- O
240 O
] O
. O

To O
test O
this O
proposition O
, O
we O
bred O
HPRT B
- I
APRT I
- I
deficient I
mice O
. O

Although O
the O
doubly O
- O
deficient O
mice O
excrete O
adenine O
and O
its O
highly O
insoluble O
derivative O
, O
2 O
, O
8 O
- O
dihydroxyadenine O
, O
which O
are O
also O
associated O
with O
human O
APRT B
deficiency I
, O
additional O
abnormalities O
or O
any O
self O
- O
injurious O
behavior O
were O
not O
detected O
. O

Thus O
, O
APRT B
- I
HPRT I
- I
deficient I
mice O
, O
which O
are O
devoid O
of O
any O
purine O
salvage O
pathways O
, O
show O
no O
novel O
phenotype O
and O
are O
not O
a O
model O
for O
the O
behavioral O
abnormalities O
associated O
with O
the O
Lesch O
- O
Nyhan O
syndrome O
as O
previously O
suggested O

Atm O
- O
deficient O
mice O
are O
retarded O
in O
growth O
, O
do O
not O
produce O
mature O
sperm O
, O
and O
exhibit O
severe O
defects O
in O
T O
cell O
maturation O
while O
going O
on O
to O
develop O
thymomas B
. O

Association O
of O
anxiety B
- I
related I
traits I
with O
a O
polymorphism O
in O
the O
serotonin O
transporter O
gene O
regulatory O
region O
. O

Association O
studies O
in O
two O
independent O
samples O
totaling O
505 O
individuals O
revealed O
that O
the O
5 O
- O
HTT O
polymorphism O
accounts O
for O
3 O
to O
4 O
percent O
of O
total O
variation O
and O
7 O
to O
9 O
percent O
of O
inherited O
variance O
in O
anxiety B
- I
related I
personality I
traits I
in O
individuals O
as O
well O
as O
sibships O
. O
. O

To O
learn O
more O
about O
the O
molecular O
basis O
of O
DTDST B
chondrodysplasias I
and O
about O
genotype O
- O
phenotype O
correlations O
, O
we O
studied O
fibroblast O
cultures O
of O
three O
new O
patients O
one O
with O
AO O
- O
2 O
, O
one O
with O
DTD O
, O
and O
one O
with O
an O
intermediate O
phenotype O
( O
AO2 O
/ O
DTD O
) O
. O

Autosomal O
dominant O
primary O
hyperparathyroidism B
and I
jaw I
tumor I
syndrome I
associated O
with O
renal O
hamartomas O
and O
cystic O
kidney O
disease O
: O
linkage O
to O
1q21 O
- O
q32 O
and O
loss O
of O
the O
wild O
type O
allele O
in O
renal O
hamartomas O
. O

Hereditary B
hyperparathyroidism I
- I
jaw I
tumor I
syndrome I
( O
HPT B
- I
JT I
) O
is O
an O
autosomal O
dominant O
disease O
( O
OMIM O
145001 O
) O
that O
has O
recently O
been O
mapped O
to O
chromosomal O
region O
1q21 O
- O
q32 O
( O
HRPT2 O
) O
. O

Here O
we O
report O
two O
families O
with O
HPT B
- I
JT I
syndrome I
in O
which O
adult B
renal I
hamartomas I
or O
cystic O
kidney O
disease O
were O
prominent O
associated O
features O
, O
possibly O
representing O
a O
new O
phenotypic O
variant O
of O
the O
HPT B
- I
JT I
syndrome I
. O

In O
the O
first O
family O
, O
renal B
lesions I
were O
present O
in O
five O
out O
of O
six O
affected O
individuals O
, O
whereas O
HPT B
and O
JT B
were O
seen O
in O
four O
and O
two O
cases O
, O
respectively O
. O

In O
the O
second O
family O
, O
JT B
was O
found O
in O
three O
of O
the O
five O
affected O
individuals O
and O
two O
affected O
members O
also O
exhibited O
polycystic B
kidney I
disease I
. O

A O
sex O
- O
dependent O
penetrance O
of O
primary B
HPT I
, O
resulting O
in O
predominantly O
male O
- O
affected O
cases O
was O
evident O
in O
the O
two O
families O
. O

Twenty O
microsatellite O
markers O
in O
the O
HRPT2 O
region O
were O
typed O
, O
in O
addition O
to O
markers O
in O
the O
multiple B
endocrine I
neoplasia I
( I
MEN I
) I
types I
1 I
and I
2 I
regions O
at O
11q13 O
and O
10q11 O
. O

The O
disease O
in O
these O
two O
kindreds O
was O
linked O
to O
five O
markers O
in O
the O
1q21 O
- O
q32 O
region O
( O
logarithm O
- O
of O
- O
odds O
scores O
3 O
. O
2 O
- O
4 O
2 O
- O
4 O
. O
2 O
) O
, O
whereas O
linkage O
to O
the O
MEN1 B
and O
MEN2 B
regions O
was O
excluded O
. O

Loss O
of O
heterozygosity O
was O
studied O
in O
seven O
renal O
hamartomas O
from O
two O
affected O
individuals O
in O
the O
first O
family O
, O
as O
well O
as O
in O
a O
jaw B
tumor I
and O
a O
parathyroid O
tumor O
from O
the O
second O
family O
. O

Mutations O
in O
the O
COL3A1 O
gene O
have O
been O
implicated O
as O
a O
cause O
of O
type B
IV I
Ehlers I
- I
Danlos I
syndrome I
, O
a O
disease O
leading O
to O
aortic B
rupture I
in O
early O
adult O
life O
. O

The O
major O
cause O
of O
death O
of O
mutant O
mice O
was O
rupture O
of O
the O
major O
blood O
vessels O
, O
similar O
to O
patients O
with O
type B
IV I
Ehlers I
- I
Danlos I
syndrome I
. O

It O
differs O
from O
this O
and O
both O
the O
classical O
and O
connatal O
forms O
of O
PMD O
in O
that O
it O
is O
relatively O
mild O
in O
form O
, O
onset O
is O
delayed O
beyond O
age O
2 O
years O
, O
nystagmus B
is O
absent O
, O
tremors B
are O
prominent O
, O
mental O
retardation O
is O
not O
severe O
, O
some O
patients O
show O
dementia B
or O
personality B
disorders I
, O
the O
disease O
is O
progressive O
rather O
than O
static O
in O
some O
, O
and O
several O
females O
show O
signs O
of O
disease O
. O

Kniest O
dysplasia O
is O
a O
severe O
chondrodysplasia O
caused O
by O
the O
defective B
formation I
of I
type I
II I
collagen I
. O

Heterogeneity O
in O
Schwartz B
- I
Jampel I
chondrodystrophic I
myotonia I
. O

The O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively O
inherited O
condition O
defined O
by O
myotonia O
, O
short O
stature O
, O
and O
bone B
dysplasia I
. O

Genetic O
linkage O
between O
SJS B
and O
chromosomal O
region O
1q36 O
- O
34 O
has O
been O
observed O
in O
several O
families O
, O
but O
the O
gene O
has O
not O
yet O
been O
identified O
. O

In O
addition O
, O
we O
tested O
genetic O
linkage O
to O
the O
SJS B
locus O
on O
chromosome O
1 O
in O
one O
family O
with O
two O
affected O
sibs O
. O

We O
found O
that O
a O
group O
of O
patients O
have O
mild O
skeletal O
changes O
which O
may O
be O
secondary O
consequences O
of O
myotonia O
, O
while O
another O
group O
of O
patients O
appear O
to O
have O
primary O
bone B
dysplasia I
with O
myotonia O
. O

We O
tentatively O
isolate O
three O
different O
types O
of O
SJS B
type I
1A I
, O
usually O
recognized O
in O
childhood O
, O
with O
moderate O
bone B
dysplasia I
, O
corresponding O
to O
the O
original O
descriptions O
of O
Schwartz O
, O
Jampel O
and O
Aberfeld O
; O
type O
1B O
, O
similar O
to O
type O
1A O
but O
recognizable O
at O
birth O
, O
with O
more O
pronounced O
bone B
dysplasia I
resembling O
Kniest O
dysplasia O
; O
and O
type O
2 O
, O
manifest O
at O
birth O
, O
with O
increased O
mortality O
and O
bone B
dysplasia I
resembling O
Pyle B
disease I
. O

Genetic O
analysis O
of O
the O
family O
with O
two O
sibs O
affected O
by O
SJS B
type I
2 I
showed O
evidence O
against O
linkage O
to O
chromosome O
1p36 O
- O
34 O
. O

CONCLUSIONS O
SJS B
is O
clinically O
and O
radiologically O
heterogeneous O
. O

The O
causes O
of O
heterogeneity O
are O
not O
known O
yet O
but O
are O
likely O
to O
include O
both O
different O
mutations O
at O
the O
SJS B
locus O
on O
chromosome O
1 O
and O
the O
presence O
of O
a O
second O
SJS B
locus O
. O

Mutations O
in O
the O
WT1 O
gene O
were O
anticipated O
to O
explain O
the O
genetic O
basis O
of O
the O
childhood O
kidney B
cancer I
, O
Wilms O
tumour O
( O
WT O
) O
. O

While O
only O
5 O
% O
of O
sporadic O
Wilms O
tumours O
have O
intragenic O
WT1 O
mutations O
, O
> O
90 O
% O
of O
patients O
with O
the O
Denys O
- O
Drash O
syndrome O
( O
renal O
nephropathy O
, O
gonadal B
anomaly I
, O
predisposition O
to O
WT O
) O
carry O
constitutional O
intragenic O
WT1 O
mutations O
. O

WT1 O
mutations O
have O
also O
been O
reported O
in O
juvenile B
granulosa I
cell I
tumour I
, O
non O
- O
asbestos O
related O
mesothelioma O
, O
desmoplastic O
small O
round O
cell O
tumour O
and O
, O
most O
recently O
, O
acute B
myeloid I
leukemia I
. O
. O

Insulin O
gene O
region O
contributes O
to O
genetic O
susceptibility O
to O
, O
but O
may O
not O
to O
low O
incidence O
of O
, O
insulin B
- I
dependent I
diabetes I
mellitus I
in O
Japanese O
. O

In O
the O
Caucasian O
population O
, O
it O
has O
been O
demonstrated O
that O
the O
insulin O
gene O
( O
INS O
) O
region O
contains O
the O
insulin B
- I
dependent I
diabetes I
mellitus I
locus O
( O
IDDM2 O
) O
. O

atm O
and O
p53 O
cooperate O
in O
apoptosis O
and O
suppression O
of O
tumorigenesis O
, O
but O
not O
in O
resistance O
to O
acute B
radiation I
toxicity I
. O

Finally O
- O
and O
in O
contrast O
to O
prior O
predictions O
- O
atm O
and O
p53 O
do O
not O
appear O
to O
interact O
in O
acute B
radiation I
toxicity I
, O
suggesting O
a O
separate O
atm O
effector O
pathway O
for O
this O
DNA O
damage O
response O
and O
having O
implications O
for O
the O
prognosis O
and O
treatment O
of O
human O
tumours O
. O
. O

Adult B
onset I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
) O
: O
analysis O
of O
galactosylceramidase O
cDNA O
from O
four O
Japanese O
patients O
. O

We O
examined O
galactosylceramidase O
( O
GALC O
) O
cDNA O
in O
four O
Japanese O
patients O
with O
adult B
onset I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
; O
AO B
- I
GLD I
) O
by O
polymerase O
chain O
reaction O
/ O
single O
- O
strand O
conformation O
polymorphism O
( O
PCR O
- O
SSCP O
) O
analysis O
, O
subsequent O
sequence O
determination O
, O
and O
restriction O
enzyme O
digestion O
of O
PCR O
products O
, O
initial O
symptoms O
were O
the O
onset O
of O
slowly O
progressive O
spastic B
paraplegia I
from O
the O
middle O
of O
the O
second O
decade O
, O
and O
all O
patients O
had O
diminished B
GALC I
activity I
in O
their O
leukocytes O
. O

Three O
mutations O
, O
viz O
. O
, O
G270D O
, O
L618S O
, O
and O
exon O
- O
6 O
skipping O
( O
535 O
- O
573del O
) O
, O
produced O
diminished B
GALC I
activity I
as O
expected O
. O

AO B
- I
GLD I
mutations O
, O
including O
those O
found O
here O
, O
are O
located O
in O
the O
N O
- O
terminus O
( O
I66M O
, O
G270D O
, O
535 O
- O
573del O
) O
or O
C O
- O
terminus O
( O
L618S O
) O
of O
the O
GALC O
enzyme O
, O
whereas O
the O
reported O
mutations O
in O
the O
infantile O
form O
( O
IF B
- I
GLD I
) O
are O
in O
the O
central O
domain O
. O

This O
difference O
in O
mutation O
sites O
may O
affect O
the O
clinical O
features O
of O
GLD B
. O

